Deutsche Bank AG Acquires New Shares in Alumis Inc. $ALMS

Key Points

• Deutsche Bank acquired 84,113 Alumis shares during the second quarter, worth approximately $2.37 million and representing about 0.07% of the company. Several other institutional investors also increased their positions.
• Alumis shares opened at $23.21, down 1.7%, after the company reported a quarterly loss of $1.11 per share and revenue of $1.66 million, missing analyst expectations for both.
• Analyst sentiment remains a “Moderate Buy,” with an average price target of $40.30, although ratings range from Strong Buy to Sell. Company insiders sold nearly 20,000 shares worth approximately $534,000 over the past quarter.

Deutsche Bank AG bought a new position in shares of Alumis Inc. (NASDAQ:ALMS - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 84,113 shares of the company's stock, valued at approximately $2,367,000. Deutsche Bank AG owned about 0.07% of Alumis at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Samsara Biocapital LLC grew its position in shares of Alumis by 19.9% during the 4th quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company's stock worth $56,188,000 after buying an additional 955,614 shares during the period. Vanguard Group Inc. raised its position in shares of Alumis by 18.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company's stock valued at $16,078,000 after acquiring an additional 625,404 shares during the period. Cormorant Asset Management LP boosted its stake in Alumis by 69.3% during the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company's stock worth $35,483,000 after acquiring an additional 1,488,200 shares during the last quarter. Octagon Capital Advisors LP boosted its stake in Alumis by 11.9% during the 1st quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company's stock worth $62,360,000 after acquiring an additional 300,000 shares during the last quarter. Finally, MPM Bioimpact LLC bought a new position in shares of Alumis during the fourth quarter worth $23,443,000.

Alumis Stock Down 1.7%

ALMS stock opened at $23.21 on Friday. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -6.01 and a beta of -0.69. Alumis Inc. has a twelve month low of $3.76 and a twelve month high of $31.35. The business has a 50 day moving average price of $26.57 and a two-hundred day moving average price of $25.11.

Alumis (NASDAQ:ALMS - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.34). Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. The company had revenue of $1.66 million during the quarter, compared to analyst estimates of $3.65 million. On average, equities research analysts anticipate that Alumis Inc. will post -2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on ALMS shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alumis in a report on Tuesday, July 7th. Guggenheim raised their price target on Alumis from $32.00 to $34.00 and gave the stock a "buy" rating in a research report on Friday, May 15th. Citigroup reiterated a "neutral" rating on shares of Alumis in a report on Monday, August 17th. Chardan Capital boosted their price objective on Alumis from $38.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, May 19th. Finally, HC Wainwright reissued a "neutral" rating and set a $25.00 target price on shares of Alumis in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $40.30.

Insider Buying and Selling

In other news, insider David M. Goldstein sold 2,596 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $68,456.52. Following the sale, the insider directly owned 30,970 shares of the company's stock, valued at approximately $816,678.90. This represents a 7.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Roy C. Hardiman sold 2,692 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $70,988.04. Following the completion of the sale, the insider owned 207,746 shares of the company's stock, valued at $5,478,262.02. This trade represents a 1.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 19,953 shares of company stock worth $534,311. Corporate insiders own 33.70% of the company's stock.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

Want to see what other hedge funds are holding ALMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alumis Inc. (NASDAQ:ALMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source